Improvement with rituximab in a patient with both rheumatoid arthritis and myasthenia gravis.
Kerkeni
Samar
S
Marotte
Hubert
H
Miossec
Pierre
P
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents / Q000008:administration & dosage; D001172:Arthritis, Rheumatoid / Q000150:complications* / Q000188:drug therapy* / Q000276:immunology; D001323:Autoantibodies / Q000097:blood / Q000187:drug effects / Q000276:immunology; D001379:Azathioprine / Q000008:administration & dosage; D001402:B-Lymphocytes / Q000187:drug effects / Q000276:immunology; D015536:Down-Regulation / Q000187:drug effects / Q000276:immunology; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008875:Middle Aged; D009157:Myasthenia Gravis / Q000150:complications* / Q000188:drug therapy* / Q000276:immunology; D000069283:Rituximab; D013256:Steroids / Q000009:adverse effects; D013997:Time Factors; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D001323:Autoantibodies; D007166:Immunosuppressive Agents; D013256:Steroids; D000069283:Rituximab; D001379:Azathioprine